Connection

WEIYI PENG to Cell Line, Tumor

This is a "connection" page, showing publications WEIYI PENG has written about Cell Line, Tumor.
Connection Strength

0.383
  1. Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators. J Immunother Cancer. 2021 02; 9(2).
    View in: PubMed
    Score: 0.066
  2. Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3K? Inhibition in PTEN Loss Melanoma. Clin Cancer Res. 2019 11 01; 25(21):6406-6416.
    View in: PubMed
    Score: 0.060
  3. Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. Cell Metab. 2018 May 01; 27(5):977-987.e4.
    View in: PubMed
    Score: 0.054
  4. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016 Feb; 6(2):202-16.
    View in: PubMed
    Score: 0.046
  5. Tumor-associated galectin-3 modulates the function of tumor-reactive T cells. Cancer Res. 2008 Sep 01; 68(17):7228-36.
    View in: PubMed
    Score: 0.028
  6. The COX2 Effector Microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma. Clin Cancer Res. 2019 03 01; 25(5):1650-1663.
    View in: PubMed
    Score: 0.014
  7. CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. Cancer Discov. 2018 09; 8(9):1156-1175.
    View in: PubMed
    Score: 0.014
  8. The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. Clin Cancer Res. 2018 07 15; 24(14):3366-3376.
    View in: PubMed
    Score: 0.013
  9. HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. Nat Commun. 2017 09 06; 8(1):451.
    View in: PubMed
    Score: 0.013
  10. The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer. Clin Cancer Res. 2017 Sep 15; 23(18):5489-5501.
    View in: PubMed
    Score: 0.013
  11. Bypassing STAT3-mediated inhibition of the transcriptional regulator ID2 improves the antitumor efficacy of dendritic cells. Sci Signal. 2016 09 27; 9(447):ra94.
    View in: PubMed
    Score: 0.012
  12. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013 Mar 01; 19(5):1225-31.
    View in: PubMed
    Score: 0.009
  13. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res. 2013 Jan 15; 19(2):393-403.
    View in: PubMed
    Score: 0.009
  14. Identification of prostate-specific G-protein coupled receptor as a tumor antigen recognized by CD8(+) T cells for cancer immunotherapy. PLoS One. 2012; 7(9):e45756.
    View in: PubMed
    Score: 0.009
  15. Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood. 2012 Nov 29; 120(23):4533-43.
    View in: PubMed
    Score: 0.009
  16. Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity. 2007 Aug; 27(2):334-48.
    View in: PubMed
    Score: 0.006
  17. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science. 2005 Aug 26; 309(5739):1380-4.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.